SHARED CARE AGREEMENT Lisdexamfetamine as single agent CNS stimulant (not for combination) Clinical Indication: For Children (aged 6 years and over) and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) Version: 2 Updated: November 2021...Shared Care Agreement • August 5th, 2022
Contract Type FiledAugust 5th, 2022The Shared Care Agreement (SCA) is intended to facilitate the accessibility and safe prescribing of complex treatments across the secondary/primary care interface. It does not contain all of the relevant product information, which should be sought using the current British National Formulary and Manufacturer’s Summary of Product Characteristics.